NGL Fine-Chem Ltd. · NSE:NGLFINE
NGL Fine-Chem — Q2 FY27 Earnings Presentation
18 slides from NGL Fine-Chem's earnings presentation, Nov 10, 2026
Slide 1: Exchange submission letter for Q2FY27 investor presentation
November 10, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor, Plot No.C/1, G Block, Dalal Street, Fort, Bandra Kurla Complex, Bandra East, Mumbai 400 001. Mumbai 400051. Scrip Code: 524774 Symbol: NGLFINE Dear Sir/Madam, Sub: Investor Pr
Slide 2: NGL Fine-Chem Investor Presentation Q2 FY27
NGL Fine-Chem Limited INVES TOR PRESENTATION Q 2 FY 27
Slide 3: Disclaimer
Disclaimer This investor presentation has been prepared by NGL Fine-Chem Limited and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied should not be d
Slide 4: Inside This Presentation
Inside Pg. No. Pg. No. This Presentation 04 10 Q2FY27 Over view, Highlights Key Strengths and Strategy Pg. No. 15 Historical Financial Performance
Slide 5: Q2FY27 Highlights
01 Q2FY27 Highlights 05 M AN A GEM E NT COM M E N TA RY 06 Q UAR TE RLY O P ERAT I ON A L M ET RI C S 07 SU M M A RY OF P RO F I T A ND LO SS S TAT EM E NT 08 SU M M A RY OF B A L AN C E SH EET 09 SU M M A RY OF CA SH F LO W S TAT EM E NT
Slide 6: Management Commentary
MANAGEMENT COMMENTARY Dear Shareholders, “Q 2F Y 2 7 wa s a s tr on g q u a rt e r, ma rk e d b y ro b us t In th e n e a r te r m, th e n e w ca pa cit y wi ll se r v e d e ma n d a cro ss o u r p r od u ct se g me n ts a n d u n r eg u la te d m a rk e ts , wh i ch g iv e s u s am pl e g e og r ap
Slide 7: Quarterly Operational Metrics
Quarterly Operational Metrics SEGMENTAL REVENUE MIX PRODUCT CONCENTRATION PARTICULARS Q2FY26 Q1FY27 Q2FY27 PARTICULARS Q2FY26 Q1FY27 Q2FY27 ANIMAL API 90% 95% 95% TOP 3 PRODUCTS 32% 31% 29% HUMAN API 4% 3% 3% TOP 5 PRODUCTS 46% 48% 43% INTERMEDIATES 5% 1% 1% TOP 10 PRODUCTS 69% 68% 65% FORMULATIONS
Slide 8: Summary of Profit and Loss Statement
Summary of Profit and Loss Statement ₹ I N C R OR ES PA RT ICUL ARS Q2FY26 Q1FY27 Q2FY27 Q-o-Q Y-o-Y REVENUE FROM OPERA TIO NS 120.26 139.16 158.71 14.05% 31.97% OTHER INCO ME 2.05 7.43 1.20 -83.85% -41.46% TOTAL INCO ME 122.31 146.59 159.91 9.09% 30.74% TOTA L OPERATING EX PENSES 103.10 115.88 130.
Slide 9: Summary of Balance Sheet
Summary of Balance Sheet ₹ I N C R OR ES PA RT ICUL ARS FY2 6 H1FY27 SHAREH OLDERS FUND 329.23 362.61 NO N CURRENT LIA BILI TIES 66.25 67.50 LONG TERM BO RRO WINGS 56.40 50.68 CURRENT LIABI LITIES 150.01 197.64 SHO RT TERM BORRO WINGS 52.02 71.43 TOTAL EQ UITY AND LIABILITIES 545.50 627.75 NO N CURR
Slide 10: Summary of Cash Flow Statement
Summary of Cash Flow Statement ₹ I N C R OR ES PA RT ICUL ARS FY2 6 H1FY27 CAS H FLO W FROM O PERATING A CTI VI TIES 43.32 35.80 CAS H FLO W FROM I NVES TING A CTI VITIES (70.59) (44.05) CAS H FLO W FROM FINANCING AC TIVITIES 29.55 10.50 NET CA SH FLO W 2.27 2.24 CAS H AT THE BEGI NNING OF YEAR 0.53
Slide 11: Overview, Strengths and Strategy
02 Overview, Strengths and Strategy 11 L EA DI N G AN I M AL HEA LT H CO M PAN Y 12 L EA DER SHI P I N V ET ERI N A RY AP I SE GM EN T 13 STATE - O F - T HE - AR T M AN U FA CT UR I N G CA PA B I LI T I ES 14 ST RAT EGY F O R N E X T LE G OF GRO W TH
Slide 12: Leading Animal Health Company
Leading Animal Health Company COMPREHENSIVE MARKET MANUFACTURING LARGE GLOBAL LONG STANDING PRODUCT LEADERSHIP EXCELLENCE PRESENCE CUSTOMER PORTFOLIO IN VETERINARY API RELATIONSHIPS • 45 APIs (43 Veterinary • Market leadership in • 3 state of the art • Strong presence • ~451 customers APIs, 2 Human
Slide 13: Leadership in Veterinary API Segment
Leadership in Veterinary API Segment REVENUE FROM VETERINARY CUSTOMER & PRODUCT Strong controls of processes with 95% in-hous e manufacturing and API SEGMENT (₹ I N CRORE S) 13% CAGR CONCENTRATION (OF SALES FY26) backward integrated facilities leading to cost competitivenes s FY26 466 CUSTOMER PRODU
Slide 14: State-of-the-art Manufacturing Capabilities
State-of-the-art Manufacturing Capabilities HIGHLIGHTS 5 manufacturing facilities located at Tarapur & Navi 20,000 m 2 168 kl 253 kl AREA OF GLASS-LINED STAINLESS STEEL Mumbai, Maharashtra, MANUFACTURING REACTORS REACTORS designed to meet the FACILITIES requirements of regulatory agencies and are ca
Slide 15: Strategy for next leg of growth
Strategy for next leg of growth BRO W N FIE LD E XP AN S IO N • Completed expansion in ONGOING INITIATIVES subsidiary Macrotech TO INCREASE • Additional capacities of a CAPACITIES TO MEET intermediates GROW ING DEMAND • Commercial production started GR EE NF IEL D EX P ANS IO N AT TARA PU R • Capaci
Slide 16: Historical Financial Performance
03 Historical Financial Performance 16 RO B U ST FI N A N CI A L P ER F OR M AN CE
Slide 17: Robust Financial Performance
Robust Financial Performance REVENUE EBITDA PAT (₹ I N C RO R ES) (₹ I N C RO R ES) (₹ I N C RO R ES) FY26 501 FY26 73 FY26 48 FY25 368 FY25 34 FY25 21 FY24 339 FY24 53 FY24 41 FY23 278 FY23 34 FY23 21 FY22 318 FY22 68 FY22 50 0 10 0 20 0 30 0 40 0 50 0 60 0 0 10 20 30 40 50 60 70 80 0 10 20 30 40 5
Slide 18: Thank You
FOR ANY FURTHER INFORMATION, PLEASE CONTACT Thank You Shivam Gharat Abhishek Mehra N GL F IN E - C HE M T IL AD VI SO R S P RI VA T E L I MI T E D L I MI T E D [email protected] m abhishek@t heinvestmentlab.in +91 22 40842222 +91 95588 14500 Corporate Office 3 0 1, E - s q uare , S ub has h Ro a d,